CKM prevention Cardiovascular · Kidney · Metabolic

Make prevention visible.

A clinical decision-support engine for every clinician in CKM care.

Explore your patient's risk continuum over time, compare modeled prevention scenarios together, and carry the conversation into the note.

Create a free account Discuss a pilot

Deterministic engine · Auditable calculations · Clinician-reviewed output

Use de-identified chart text only. Do not enter names, dates of birth, MRNs or other patient identifiers.

Try the simulator ↓ · Sign in

Try a plan

What happens if…

Start a statin? Bring her blood pressure down? Answer it in the room. Tap an intervention and RCCKM reruns the whole assessment for that scenario.

PREVENT population model

Risk and plan

Tap an intervention and watch the picture change. Each scenario is a full engine run.

^† Trial-derived treatment effect ^* Recalculated risk factor, not a treatment effect

TodayWith plan

100 similar patients over 30 years PREVENT model

12 may have a heart attack or stroke

Points are PREVENT's 10-year and 30-year estimates; the dotted lines only connect them. The 30-year plan value assumes the treatment effect is sustained. Demo patient; every value is RCCKM engine output.

Playing a demo. Tap a lever to take over.

Next steps

Every recommendation shows its work.

Each step traces back to the patient’s values and the guideline behind it, including the test that was never ordered.

Same 52-year-old demo patient as the simulator. Every line is RCCKM engine output.

Next steps

Action

1Lipid loweringModerate-intensity statin reasonableLDL-C 122. If treatment is selected: LDL-C goal <100.
2PlaqueConsider CACPlaque not measured
Why this stepAge 52 · 10-yr PREVENT 2.12% · 30-yr PREVENT 12.17%
ACC/AHA 2026Audit trail
3Kidney protectionStable
4Blood pressureContinue routine BP surveillance
5Glycemia / metabolicBMI ≥30: consider GLP-1 RA for weight and cardiometabolic riskA1c 6.1%.
6AspirinNot indicated

See it run

From chart text to a plan in about a minute.

One demo patient, the way a visit actually goes: paste, apply, assess, review, and try a plan when there’s a decision to make.

RCCKM · Paste

Example Epic SmartPhrase. Not real patient data.

=== CARDIOVASCULAR RISK ASSESSMENT ===

Age: 58 y.o.
Sex: male
Race/Ethnicity: White (non-Hispanic)

Smoking status:   Tobacco Use
    Smoking status: Never
    Passive exposure: Never
    Smokeless tobacco: Never


Blood pressure (most recent):
BP Readings from Last 3 Encounters:
10/22/26	138/84
07/23/26	(!) 142/86
04/16/26	(!) 146/88

BMI: @LAST_BMI@
Body mass index is 35.59 kg/m².
Estimated body mass index is 35.59 kg/m² as calculated from the following:
  Height as of this encounter: 1.778 m (5' 10").
  Weight as of this encounter: 112.5 kg (248 lb 0.3 oz).
Wt Readings from Last 5 Encounters:
10/22/26	112.5 kg (248 lb 0.3 oz)
07/23/26	111.1 kg (244 lb 14.9 oz)
04/16/26	109.8 kg (242 lb 1.1 oz)
10/23/25	106.6 kg (235 lb 0.2 oz)
10/24/24	104.3 kg (229 lb 15.1 oz)


Clinical ASCVD: No
No history of myocardial infarction, angina, coronary revascularization, ischemic stroke, TIA, or peripheral arterial disease.
No history of heart failure or atrial fibrillation.

Family History:
Premature ASCVD in first-degree relative: Yes
Relationship: Father
Event type: Myocardial infarction (father)
Age at event: 49

Lab Results
Component	Value	Date
	NA	138	10/22/2026
	K	4.6	10/22/2026
	CL	103	10/22/2026
	CO2	25	10/22/2026
	BUN	24 (H)	10/22/2026
	CREATININE	1.45 (H)	10/22/2026
	GLUCOSE	151 (H)	10/22/2026
	CALCIUM	9.4	10/22/2026
	PROT	7.2	10/22/2026
	LABALBU	4.2	10/22/2026
	BILITOT	0.6	10/22/2026
	ALKPHOS	74	10/22/2026
	AST	28	10/22/2026

Example Epic SmartPhrase

Clinical PearlAI · optional

Generate Clinical Pearl

Persistent A2 albuminuria (UACR 126 mg/g) with eGFR 56 (G3a) plus diabetes shifts this patient from routine diabetes prevention to a cardiorenal phenotype: the kidney findings together with diabetes drive the high-intensity statin, SGLT2 inhibitor and GLP-1 recommendations, and UACR is already counted in the PREVENT full-model estimate.

Clinical Pearl · Not a substitute for clinical judgment · Example output, lightly edited

Clinical report · EMR plain text

Risk Continuum CKM™Level 3C | Compounding drivers | CKM 3 (total CVD ≥20%) | G3aA2 | CAC Not MeasuredPREVENT ASCVD: 10y 14.5% (High), 30y 37.1% (High) | Total CVD: 10y 22.9%, 30y 53.7% Assessment (ICD-10):- T2DM with CKD G3aA2 (E11.22, N18.31)- Primary hypertension (I10)- Elevated lipoprotein(a) (E78.41)- Hypertriglyceridemia (E78.1)- Obesity, BMI 35.6 (E66.9, Z68.35)- Metabolic dysfunction-associated steatotic liver disease (K76.0)- Obstructive sleep apnea (G47.33) Risk Drivers:ApoB 116 mg/dL | T2DM with CKD G3aA2 | Lp(a) 168 nmol/L | hsCRP 2.8 mg/L (dated 2026-10-22; 10 days before assessment; single measurement; confirm persistence/context) Management Considerations:- Lipids: Currently receiving atorvastatin 20 mg. Intensify to high-intensity or maximally tolerated statin therapy based on the independent risk indication. LDL-C 126; target <70. If still above goal on maximally tolerated statin, consider add-on nonstatin therapy.- Plaque: Consider CAC.- Kidney: Optimize kidney protection. SGLT2i beneficial if no contraindication (T2D with CKD; eGFR 56; UACR 126). ACEi/ARB active. G3a/A2 kidney-risk pattern.- BP: Confirm BP; optimize RAAS if persistent. Current BP 138/84 mmHg.- Metabolic: Diabetes control worsening. A1c 7.5%, worsened from 6.4%; above goal; on current therapy; review regimen; Recommend GLP-1/GLP-1-GIP for glycemic, cardiovascular, cardiorenal, and weight benefits.- Aspirin: Not indicated.

Demo patient, 58M, Level 3C (Compounding drivers). The simulator above uses a different patient, 52F, Level 3B (Actionable drivers). Each sample keeps its own engine-assigned Level. Modeled plan estimates are for clinician review, not treatment orders.

90%

of U.S. adults meet criteria for CKM syndrome. Nearly half are at stage 2, with metabolic risk factors or kidney disease, where prevention has the most room to work.

Aggarwal et al., JAMA, 2024

15 min

is the median primary care visit. The evidence is ready; bringing the whole cardiometabolic picture together in that time is the opportunity.

Neprash et al., Medical Care, 2021

47%

of U.S. adults 40–75 without heart disease are eligible for cholesterol-lowering therapy, and about 23% take it. A clear risk conversation at the point of care can help close that gap.

Alexander et al., J Gen Intern Med, 2025

Shared decision making

Make the decision together, with the numbers on the screen.

Patients decide better when they can see their own risk and what each option would change. RCCKM gives you something to point at, a way to try options together, and a record of what you talked about.

👥

Risk they can picture

"About 2 in 100 similar patients," with a 100-person array at 10 and 30 years.

📉

A curve they can watch bend

Today and the plan on one timeline, out to age 82 for this patient.

📝

The conversation, documented

"Risk Reduction Discussed" goes in the note with the numbers you shared.

For the patient

Your Prevention Roadmap

Copy to after-visit summaryPrint

Step 1

Where you stand

10-year risk2.12%About 2 in 100 similar patients

30-year risk12.17%About 12 in 100 similar patients

Coronary plaque: not measured.

Step 2

Why your risk is higher

Long-term riskTriglyceridesKidney and metabolic healthCholesterol particles

Step 3

Your goals

LDL-C below 100if treatment is selected · now 122

ApoB below 90if treatment is selected · now 92

A1c below 5.7%now 6.1%

Step 4

Your next steps

Cholesterol: Discuss cholesterol-lowering medicine with your clinician.
Weight: Discuss GLP-1 or GLP-1/GIP treatment as an option for weight benefit.
Coronary plaque: Discuss a coronary calcium scan (CAC) to check for plaque.

A handout in plain language. Print it, or paste it into the after-visit summary.

Try it here

Pick a patient. Read the note RCCKM wrote.

Four demo patients, each with its own engine-generated note. RCCKM Levels describe the clinical pattern; PREVENT supplies the probability. Read the Level guide.

Clinical report · ready to paste

Who it's for

Built for every clinician in the CKM space.

🩺

Internal Medicine

Sort out which intervention to prioritize in complex patients.

🏥

Family Medicine

Follow each patient's trajectory visit after visit.

❤️

Cardiology

See the metabolic, kidney, lipid and plaque drivers upstream.

🫘

Nephrology

Kidney function, albuminuria and CV risk in one frame.

🩸

Endocrinology

Diabetes care with heart and kidney risk in view.

🤝

Care teams

Share the modeled benefit, review the note, and leave with a patient handout.

Shereef El-Ibiary, MD, founder of Risk Continuum CKM, smiling in a black polo — Shereef El-Ibiary, MD · Founder, Risk Continuum CKM

Meet the founder

Built by a physician. Grounded in clinical practice.

Shereef El-Ibiary, MD

Internal Medicine · Primary Care · Hospital Medicine · Population Health

We are at a remarkable moment in medicine. Advances in technology, treatments, and clinical evidence are opening new possibilities for prevention. Our patients’ records hold valuable information about their health and how it is changing. The opportunity now is to bring it all together, efficiently and meaningfully, at the point of care and beyond.

After nearly two decades caring for patients across primary care, hospital medicine, and population health, I built Risk Continuum CKM to help put that opportunity into practice. RCCKM connects a patient’s history, clinical findings, and trends with relevant evidence, helping clinicians see the whole picture and turn that understanding into an individualized approach to prevention.

My goal is to make comprehensive prevention easier to deliver in everyday practice. By bringing the information and evidence together, we can support clinician judgment, strengthen conversations with patients, and extend our attention from today’s decisions to long-term health.

Reconcile. Curate. Care.

"I wanted a way to figure out patients' cardiovascular risk quickly, and catch the signals to alter course well before events, using the routine data we already have or can easily get."

More birthdays. More weddings. More graduations.

Methods & evidence

Questions behind the numbers.

Explore the science, see how scenarios are built, and discover the next steps for clinical evaluation.

Read the methods

Browse the FAQs for a quick introduction.

What do the RCCKM Levels mean?

Each Level names a clinical pattern. The guide explains 3A, 3B and 3C alongside the other Levels and the separate CKM, KDIGO and PREVENT frameworks.

What does the Risk Signal Score add?

Read how the points tally makes its contributors visible and how to interpret it alongside PREVENT.

What does the simulator bring to the conversation?

Explore options together using trial-derived LDL-C and blood pressure effects and supported PREVENT recalculations, with the methods in view.

What supports the platform?

Published equations and clinical frameworks underpin the assessment. Software checks and automated case testing support development, with independent clinical evaluation as the next step.

Pilots

Help evaluate prevention in the visit.

We're seeking practices, specialty groups and health systems to evaluate RCCKM's simulator, clinical note and patient handout.

For platform teams, let's explore how the engine could support your existing workflow.

Start with a 15-minute demo on your own de-identified cases. Clinical pilots and integrations require separate institutional approvals and agreements.

🏥

Tell us about your team.

Send a note, or email shereef@riskcontinuum.health.